| Literature DB >> 26376919 |
Chen-Yi Liao1, Shih-Chung Huang2, Cheng-Hui Lin3, Chih-Chiang Wang4, Mei-Yu Liu5, Ren-Jy Ben6, Wu-Hsien Kuo7, Ching-Chang Lee8.
Abstract
INTRODUCTION: Symmetrical peripheral gangrene is an uncommon but devastating complication in critically ill patients, and it has a high mortality. It is seen in a wide variety of medical conditions, presenting as symmetrical gangrene of two or more extremities without large blood vessel obstruction. CASEEntities:
Mesh:
Substances:
Year: 2015 PMID: 26376919 PMCID: PMC4573942 DOI: 10.1186/s13256-015-0688-3
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Survey for symmetrical peripheral gangrene
| Laboratory test (normal values) | Laboratory value |
|---|---|
| HBsAg | Nonreactive |
| HCV antibody | Nonreactive |
| Cryoglobulin | Negative |
| ESR, mm/h (0–15) | 69mm/h |
| RPR/VDRL test | Negative |
| Cold agglutinin antibodies (<1:16×(−); 1:16X(+)) | <1:16 |
| C3, mg/dl (86–160) | 143 |
| C4, mg/dl (17–45) | 30 |
| Protein C, % (70–140%) | 78.7 |
| Anti-thrombin III, % (75–125%) | 73.4 |
| c-ANCA, IU/ml (<2) | 0.1 |
| ANA (<1:20) | <1:20 |
| Anti-DNA, <Day 12 after admission10(−); 10–15(+/−); >15(+) | 0.1(−) |
| Anti-cardiolipin IgM, MPL U/ml (<10) | 0.1 |
| Anti-cardiolipin IgG, IU/ml (<10) | 0.2 |
| DIC profile | |
| Platelets (150,000–400,000/μl) | 170,000/μl |
| PT, s (8.0–12.0) | 12.5 |
| INR | 1.27 |
| aPTT, s (24.3–32.7) | 33.1 |
| D-dimer, ng/ml (<500) | 4441.30 |
| Fibrinogen, mg/dl (150–350) | 559.5 |
| CEA, ng/ml (0–5) | 3.77 |
| AFP, ng/ml (1.09–8.04) | 3.20 |
| CA 19-9, U/ml (0–37) | 6.52 |
| PSA, ng/ml (0–4) | 0.622 |
AFP, α-fetoprotein; ANA, anti-nuclear antibodies; c-ANCA, cytoplasmic anti-neutrophil cytoplasmic antibodies; aPTT, activated partial thromboplastin time; C3, complement component 3; C4, complement component 4; CA 19-9, carbohydrate antigen 19-9; c-ANCA, cytoplasmic anti-neutrophil cytoplasmic antibodies; CEA, carcinoembryonic antigen; DIC, Disseminated intravascular coagulation; ESR, erythrocyte sedimentation rate; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; Ig, immunoglobulin; INR, international normalized ratio; PSA, prostate-specific antigen; PT, prothrombin time; RPR/VDRL, rapid plasma regain/venereal disease research laboratory
Fig. 1Acrocyanosis on day 9 after admission
Fig. 2a Day 12 after admission: gangrenous change over the fingers on day 9 after acrocynosis noted. b Day 26 after admission: resolution of symmetrical peripheral gangrene on day 22 after acrocyanosis noted.